European Commission calls out Teva over anti-competitive practice

The European Commission has called out Teva over anti-competitive behaviour centring on a pay-for-delay drug deal.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Teva responds ‘robustly’ to EU pay-for-delay charge

15 March 2018 Israeli pharmaceutical company Teva “robustly” responded to the European Commission’s charge of anti-competitive behaviour at a hearing earlier this week.

Europe

Teva loses TM appeal over ‘French version’ of slogan

9 July 2020 Drug company Teva has lost an appeal over its bid to trademark two word signs, after the tenth chamber of the EU General Court ruled in favour of the European Union IP Office (EUIPO) yesterday, July 8.

More on this story

Europe

Teva responds ‘robustly’ to EU pay-for-delay charge

15 March 2018 Israeli pharmaceutical company Teva “robustly” responded to the European Commission’s charge of anti-competitive behaviour at a hearing earlier this week.

Europe

Teva loses TM appeal over ‘French version’ of slogan

More on this story

Europe

Teva responds ‘robustly’ to EU pay-for-delay charge

15 March 2018 Israeli pharmaceutical company Teva “robustly” responded to the European Commission’s charge of anti-competitive behaviour at a hearing earlier this week.

Europe

Teva loses TM appeal over ‘French version’ of slogan